This review was undertaken to assess the nature and incidence of procedure-related changes in mice, rats and rabbits which received saline solution by intramuscular injection. Data were collected on the injection sites from 7 studies representing 152 animals. The original observations by the different study pathologists from both control and treated animals were evaluated in order to create a glossary of preferred terms to be used in toxicology studies. These standardized terms were then applied to changes observed in the saline-treated animals. The review showed that the most severe of the procedure-related lesions were only of a slight level. Two days post-injection, the local reactions were mainly composed of minimal infiltration by mononuclear cells (lymphocytes and macrophages) with occasional degeneration of myofibres. From 10 to 42 days post-injection, lesions showed regeneration of myofibres and some fibrosis. In rats, the number of injections at each site influenced inflammatory infiltrate and degenerative lesions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.etp.2008.07.003 | DOI Listing |
Neurobiol Dis
December 2024
Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Bünteweg 17, 30559 Hannover, Germany. Electronic address:
Increasing evidence points to infectious diseases as contributor to the pathogenesis of neurodegeneration in Parkinson's disease (PD), probably driven by a peripheral and CNS inflammatory response together with alpha-synuclein (aSyn) pathology. Pro-inflammatory lipopolysaccharide (LPS) endotoxin is suggested as a risk factor, and LPS shedding gram-negative bacteria are more prevalent in the gut-microbiome of PD patients. Here, we investigated whether LPS could contribute to the neurodegenerative disease progression via neuroinflammation, especially under conditions of aSyn pathology.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
December 2024
Department of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, 95 Yong'an Rd., Xicheng Dist, Beijing, 100050, China.
Purpose: Neuroblastoma (NB) is a malignant embryonic tumour with poor prognosis and high mortality rate. The antigen gisialoganglioside (GD2), which is highly expressed on the surface of NB cells, is an effective target for therapy. This study aims to evaluate the GD2 expression with [Cu]Cu-NOTA-hu3F8 positron emission tomography (PET) imaging and explore the radioimmunotherapy (RIT) effect of [Lu]Lu-DOTA-hu3F8 in NB tumour models.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
December 2024
Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, Beijing, 100050, China.
Purpose: CD30 serves as an ideal therapeutic target for lymphoma, but its variable expression and high relapse rate pose challenges in targeted therapy. This study aims to label the anti-CD30 monoclonal antibody with Cu/Lu for immuno-positron emission tomography (immuno-PET) and radioimmunotherapy (RIT).
Methods: CD30 binding kinetics of anti-CD30-IgG (IMB16) were measured by Biolayer interferometry (BLI).
Int J Mol Sci
November 2024
Arid Lands Cultivation Research Institute, City of Scientific Research and Technological Applications, New Borg El Arab, Alexandria 21934, Egypt.
Nile tilapia () and European sea bass () are economically significant species in Mediterranean countries, serving essential roles in the aquaculture industry due to high market demand and nutritional value. They experience substantial losses from bacterial pathogens and , particularly at the onset of the summer season. The immune mechanisms involved in fish infections by and remain poorly understood.
View Article and Find Full Text PDFClin Cancer Res
December 2024
Université Laval, Quebec City, QC, Canada.
Purpose: There is overwhelming interest to use actinium-225 ([225Ac]Ac) to develop targeted alpha therapies. Antibody-drug conjugates (ADCs) are highly cytotoxic. Combining [225Ac]Ac with ADC to develop an antibody-drug radioconjugate (ADR) [225Ac]Ac-Macropa-trastuzumab-PEG6-DM1, is expected to be more effective than its ADC (trastuzumab-PEG6-DM1) against breast cancer (BC).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!